collection
MENU ▼
Read by QxMD icon Read
search

Colon

shared collection
23 papers 0 to 25 followers
https://www.readbyqxmd.com/read/27733426/effectiveness-of-screening-colonoscopy-in-reducing-the-risk-of-death-from-right-and-left-colon-cancer-a-large-community-based-study
#1
Chyke A Doubeni, Douglas A Corley, Virginia P Quinn, Christopher D Jensen, Ann G Zauber, Michael Goodman, Jill R Johnson, Shivan J Mehta, Tracy A Becerra, Wei K Zhao, Joanne Schottinger, V Paul Doria-Rose, Theodore R Levin, Noel S Weiss, Robert H Fletcher
OBJECTIVE: Screening colonoscopy's effectiveness in reducing colorectal cancer mortality risk in community populations is unclear, particularly for right-colon cancers, leading to recommendations against its use for screening in some countries. This study aimed to determine whether, among average-risk people, receipt of screening colonoscopy reduces the risk of dying from both right-colon and left-colon/rectal cancers. DESIGN: We conducted a nested case-control study with incidence-density matching in screening-eligible Kaiser Permanente members...
October 12, 2016: Gut
https://www.readbyqxmd.com/read/27658908/best-of-series-colonoscopy
#2
Amit Rastogi, Sachin Wani
No abstract text is available yet for this article.
September 19, 2016: Gastrointestinal Endoscopy
https://www.readbyqxmd.com/read/27214731/population-based-colonoscopy-screening-for-colorectal-cancer-a-randomized-clinical-trial
#3
Michael Bretthauer, Michal F Kaminski, Magnus Løberg, Ann G Zauber, Jaroslaw Regula, Ernst J Kuipers, Miguel A Hernán, Eleanor McFadden, Annike Sunde, Mette Kalager, Evelien Dekker, Iris Lansdorp-Vogelaar, Kjetil Garborg, Maciej Rupinski, Manon C W Spaander, Marek Bugajski, Ole Høie, Tryggvi Stefansson, Geir Hoff, Hans-Olov Adami
IMPORTANCE: Although some countries have implemented widespread colonoscopy screening, most European countries have not introduced it because of uncertainty regarding participation rates, procedure-related pain and discomfort, endoscopist performance, and effectiveness. To our knowledge, no randomized trials on colonoscopy screening currently exist. OBJECTIVE: To investigate participation rate, adenoma yield, performance, and adverse events of population-based colonoscopy screening in several European countries...
July 1, 2016: JAMA Internal Medicine
https://www.readbyqxmd.com/read/26361970/maintenance-therapy-for-metastatic-colorectal-cancer
#4
COMMENT
Riccardo Giampieri, Stefano Cascinu
No abstract text is available yet for this article.
October 2015: Lancet Oncology
https://www.readbyqxmd.com/read/26369679/new-insights-into-the-mechanism-of-action-of-aspirin-in-the-prevention-of-colorectal-neoplasia
#5
REVIEW
Luigia Di Francesco, Luilli Antonio López Contreras, Angela Sacco, Paola Patrignani
The results of clinical studies have shown that the chronic administration of aspirin, even at the lowdoses (75-100 mg daily) recommended for the prevention of cardiovascular disease, is associated with a reduction of cancer incidence and mortality, in particular colorectal cancer (CRC). The mechanism of action of aspirin as an antineoplastic agent remains controversial. However, data of clinical pharmacology and several features of the chemopreventive effect of aspirin, emerged from clinical trials, suggest that the antiplatelet effect of aspirin plays a central role in its anticancer effects...
2015: Current Pharmaceutical Design
https://www.readbyqxmd.com/read/26338525/folfoxiri-plus-bevacizumab-versus-folfiri-plus-bevacizumab-as-first-line-treatment-of-patients-with-metastatic-colorectal-cancer-updated-overall-survival-and-molecular-subgroup-analyses-of-the-open-label-phase-3-tribe-study
#6
RANDOMIZED CONTROLLED TRIAL
Chiara Cremolini, Fotios Loupakis, Carlotta Antoniotti, Cristiana Lupi, Elisa Sensi, Sara Lonardi, Silvia Mezi, Gianluca Tomasello, Monica Ronzoni, Alberto Zaniboni, Giuseppe Tonini, Chiara Carlomagno, Giacomo Allegrini, Silvana Chiara, Mauro D'Amico, Cristina Granetto, Marina Cazzaniga, Luca Boni, Gabriella Fontanini, Alfredo Falcone
BACKGROUND: In the TRIBE study, FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus bevacizumab significantly improved progression-free survival of patients with metastatic colorectal cancer compared with FOLFIRI (fluorouracil, leucovorin, and irinotecan) plus bevacizumab. In this updated analysis, we aimed to provide mature results for overall survival-a secondary endpoint-and report treatment efficacy in RAS and BRAF molecular subgroups. METHODS: TRIBE was an open-label, multicentre, phase 3 randomised study of patients (aged 18-70 years with Eastern Cooperative Oncology Group [ECOG] performance status of 2 or less and aged 71-75 years with an ECOG performance status of 0) with unresectable metastatic colorectal cancer who were recruited from 34 Italian oncology units...
October 2015: Lancet Oncology
https://www.readbyqxmd.com/read/26034407/radiation-proctopathy
#7
REVIEW
Marc B Grodsky, Shafik M Sidani
Radiation therapy is a widely utilized treatment modality for pelvic malignancies, including prostate cancer, rectal cancer, and cervical cancer. Given its fixed position in the pelvis, the rectum is at a high risk for injury secondary to ionizing radiation. Despite advances made in radiation science, up to 75% of the patients will suffer from acute radiation proctitis and up to 20% may experience chronic symptoms. Symptoms can be variable and include diarrhea, bleeding, incontinence, and fistulization. A multitude of treatment options exist...
June 2015: Clinics in Colon and Rectal Surgery
https://www.readbyqxmd.com/read/26361971/maintenance-strategies-after-first-line-oxaliplatin-plus-fluoropyrimidine-plus-bevacizumab-for-patients-with-metastatic-colorectal-cancer-aio-0207-a-randomised-non-inferiority-open-label-phase-3-trial
#8
RANDOMIZED CONTROLLED TRIAL
Susanna Hegewisch-Becker, Ullrich Graeven, Christian A Lerchenmüller, Birgitta Killing, Reinhard Depenbusch, Claus-Christoph Steffens, Salah-Eddin Al-Batran, Thoralf Lange, Georg Dietrich, Jan Stoehlmacher, Andrea Tannapfel, Anke Reinacher-Schick, Julia Quidde, Tanja Trarbach, Axel Hinke, Hans-Joachim Schmoll, Dirk Arnold
BACKGROUND: The definition of a best maintenance strategy following combination chemotherapy plus bevacizumab in metastatic colorectal cancer is unclear. We investigated whether no continuation of therapy or bevacizumab alone are non-inferior to fluoropyrimidine plus bevacizumab, following induction treatment with a fluoropyrimidine plus oxaliplatin plus bevacizumab. METHODS: In this open-label, non-inferiority, randomised phase 3 trial, we included patients aged 18 years or older with histologically confirmed, previously untreated metastatic colorectal cancer, Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, adequate bone marrow, liver, and renal function, no pre-existing neuropathy greater than grade 1, and measurable disease, from 55 hospitals and 51 private practices in Germany...
October 2015: Lancet Oncology
https://www.readbyqxmd.com/read/26238157/annual-fecal-occult-blood-testing-can-be-safely-suspended-for-up-to-5-years-after-a-negative-colonoscopy-in-asymptomatic-average-risk-patients
#9
Jennifer Liu, Steven Finkelstein, Fritz François
OBJECTIVES: Annual fecal occult blood testing (FOBT) is often continued in patients who have had a recent negative colonoscopy, despite recommendations to the contrary. This prospective study aimed to determine the proportion of patients with a positive FOBT who had adenomas and cancers on colonoscopy stratified according to the duration of time since the last negative colonoscopy. METHODS: A total of 1,119 asymptomatic average-risk patients ≥50 years of age referred for a positive FOBT were prospectively identified and stratified by the duration of time since the last colonoscopy (never, >10 years, 5-10 years, or <5 years)...
September 2015: American Journal of Gastroenterology
https://www.readbyqxmd.com/read/26201822/should-preoperative-chest-computed-tomography-be-performed-in-all-patients-with-colorectal-cancer
#10
A R Lazzaron, M V Vieira, D C Damin
AIM: This study evaluated the accuracy of chest computed tomography (CCT) in the preoperative staging of patients with potentially resectable colorectal cancer (CRC). An attempt was made to determine whether CCT has a significant influence on management and clinical outcome. METHOD: A review was conducted of all preoperative CCTs and X-rays performed in patients submitted to elective resection of CRC at our institution between 2005 and 2012. All scans were revised by an independent radiologist who was unaware of the circumstances of each case...
October 2015: Colorectal Disease: the Official Journal of the Association of Coloproctology of Great Britain and Ireland
https://www.readbyqxmd.com/read/26162432/cost-considerations-in-the-evaluation-and-treatment-of-colorectal-cancer
#11
REVIEW
Veena Shankaran
As the cost of cancer care in the United States continues to climb at an alarming rate, it is critically important for the oncology community to begin embracing interventions that provide value to patients and society. This is particularly important in the field of colorectal cancer, where many new high-priced drugs have emerged over the past several years. While adjuvant chemotherapy (FOLFOX and capecitabine) has been shown to fall within accepted thresholds for cost-effectiveness, many interventions in the metastatic setting have not...
August 2015: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/26126485/irritable-bowel-syndrome-and-colorectal-neoplasia-cause-and-effect-or-chance-association
#12
COMMENT
Pavit Luthra, Alexander C Ford
No abstract text is available yet for this article.
August 2015: Gastroenterology
https://www.readbyqxmd.com/read/25862517/maintenance-treatment-with-capecitabine-and-bevacizumab-in-metastatic-colorectal-cancer-cairo3-a-phase-3-randomised-controlled-trial-of-the-dutch-colorectal-cancer-group
#13
RANDOMIZED CONTROLLED TRIAL
Lieke H J Simkens, Harm van Tinteren, Anne May, Albert J ten Tije, Geert-Jan M Creemers, Olaf J L Loosveld, Felix E de Jongh, Frans L G Erdkamp, Zoran Erjavec, Adelheid M E van der Torren, Jolien Tol, Hans J J Braun, Peter Nieboer, Jacobus J M van der Hoeven, Janny G Haasjes, Rob L H Jansen, Jaap Wals, Annemieke Cats, Veerle A Derleyn, Aafke H Honkoop, Linda Mol, Cornelis J A Punt, Miriam Koopman
BACKGROUND: The optimum duration of first-line treatment with chemotherapy in combination with bevacizumab in patients with metastatic colorectal cancer is unknown. The CAIRO3 study was designed to determine the efficacy of maintenance treatment with capecitabine plus bevacizumab versus observation. METHODS: In this open-label, phase 3, randomised controlled trial, we recruited patients in 64 hospitals in the Netherlands. We included patients older than 18 years with previously untreated metastatic colorectal cancer, with stable disease or better after induction treatment with six 3-weekly cycles of capecitabine, oxaliplatin, and bevacizumab (CAPOX-B), WHO performance status of 0 or 1, and adequate bone marrow, liver, and renal function...
May 9, 2015: Lancet
https://www.readbyqxmd.com/read/25117129/effect-of-flexible-sigmoidoscopy-screening-on-colorectal-cancer-incidence-and-mortality-a-randomized-clinical-trial
#14
RANDOMIZED CONTROLLED TRIAL
Øyvind Holme, Magnus Løberg, Mette Kalager, Michael Bretthauer, Miguel A Hernán, Eline Aas, Tor J Eide, Eva Skovlund, Jørn Schneede, Kjell Magne Tveit, Geir Hoff
IMPORTANCE: Colorectal cancer is a major health burden. Screening is recommended in many countries. OBJECTIVE: To estimate the effectiveness of flexible sigmoidoscopy screening on colorectal cancer incidence and mortality in a population-based trial. DESIGN, SETTING, AND PARTICIPANTS: Randomized clinical trial of 100,210 individuals aged 50 to 64 years, identified from the population of Oslo city and Telemark County, Norway. Screening was performed in 1999-2000 (55-64-year age group) and in 2001 (50-54-year age group), with follow-up ending December 31, 2011...
August 13, 2014: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/23414648/computed-tomographic-colonography-versus-barium-enema-for-diagnosis-of-colorectal-cancer-or-large-polyps-in-symptomatic-patients-siggar-a-multicentre-randomised-trial
#15
RANDOMIZED CONTROLLED TRIAL
Steve Halligan, Kate Wooldrage, Edward Dadswell, Ines Kralj-Hans, Christian von Wagner, Rob Edwards, Guiqing Yao, Clive Kay, David Burling, Omar Faiz, Julian Teare, Richard J Lilford, Dion Morton, Jane Wardle, Wendy Atkin
BACKGROUND: Barium enema (BE) is widely available for diagnosis of colorectal cancer despite concerns about its accuracy and acceptability. Computed tomographic colonography (CTC) might be a more sensitive and acceptable alternative. We aimed to compare CTC and BE for diagnosis of colorectal cancer or large polyps in symptomatic patients in clinical practice. METHODS: This pragmatic multicentre randomised trial recruited patients with symptoms suggestive of colorectal cancer from 21 UK hospitals...
April 6, 2013: Lancet
https://www.readbyqxmd.com/read/24047060/long-term-mortality-after-screening-for-colorectal-cancer
#16
RANDOMIZED CONTROLLED TRIAL
Aasma Shaukat, Steven J Mongin, Mindy S Geisser, Frank A Lederle, John H Bond, Jack S Mandel, Timothy R Church
BACKGROUND: In randomized trials, fecal occult-blood testing reduces mortality from colorectal cancer. However, the duration of the benefit is unknown, as are the effects specific to age and sex. METHODS: In the Minnesota Colon Cancer Control Study, 46,551 participants, 50 to 80 years of age, were randomly assigned to usual care (control) or to annual or biennial screening with fecal occult-blood testing. Screening was performed from 1976 through 1982 and from 1986 through 1992...
September 19, 2013: New England Journal of Medicine
https://www.readbyqxmd.com/read/23128861/rescreening-of-persons-with-a-negative-colonoscopy-result-results-from-a-microsimulation-model
#17
Amy B Knudsen, Chin Hur, G Scott Gazelle, Deborah Schrag, Elizabeth G McFarland, Karen M Kuntz
BACKGROUND: Persons with a negative result on screening colonoscopy are recommended to repeat the procedure in 10 years. OBJECTIVE: To assess the effectiveness and costs of colonoscopy versus other rescreening strategies after an initial negative colonoscopy result. DESIGN: Microsimulation model. DATA SOURCES: Literature and data from the Surveillance, Epidemiology, and End Results program. TARGET POPULATION: Persons aged 50 years who had no adenomas or cancer detected on screening colonoscopy...
November 6, 2012: Annals of Internal Medicine
https://www.readbyqxmd.com/read/24430319/effect-of-3-to-5-years-of-scheduled-cea-and-ct-follow-up-to-detect-recurrence-of-colorectal-cancer-the-facs-randomized-clinical-trial
#18
RANDOMIZED CONTROLLED TRIAL
John N Primrose, Rafael Perera, Alastair Gray, Peter Rose, Alice Fuller, Andrea Corkhill, Steve George, David Mant
IMPORTANCE: Intensive follow-up after surgery for colorectal cancer is common practice but is based on limited evidence. OBJECTIVE: To assess the effect of scheduled blood measurement of carcinoembryonic antigen (CEA) and computed tomography (CT) as follow-up to detect recurrent colorectal cancer treatable with curative intent. DESIGN, SETTING, AND PARTICIPANTS: Randomized clinical trial in 39 National Health Service hospitals in the United Kingdom; 1202 eligible participants were recruited between January 2003 and August 2009 who had undergone curative surgery for primary colorectal cancer, including adjuvant treatment if indicated, with no evidence of residual disease on investigation...
January 15, 2014: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/23177514/regorafenib-monotherapy-for-previously-treated-metastatic-colorectal-cancer-correct-an-international-multicentre-randomised-placebo-controlled-phase-3-trial
#19
RANDOMIZED CONTROLLED TRIAL
Axel Grothey, Eric Van Cutsem, Alberto Sobrero, Salvatore Siena, Alfredo Falcone, Marc Ychou, Yves Humblet, Olivier Bouché, Laurent Mineur, Carlo Barone, Antoine Adenis, Josep Tabernero, Takayuki Yoshino, Heinz-Josef Lenz, Richard M Goldberg, Daniel J Sargent, Frank Cihon, Lisa Cupit, Andrea Wagner, Dirk Laurent
BACKGROUND: No treatment options are available for patients with metastatic colorectal cancer that progresses after all approved standard therapies, but many patients maintain a good performance status and could be candidates for further therapy. An international phase 3 trial was done to assess the multikinase inhibitor regorafenib in these patients. METHODS: We did this trial at 114 centres in 16 countries. Patients with documented metastatic colorectal cancer and progression during or within 3 months after the last standard therapy were randomised (in a 2:1 ratio; by computer-generated randomisation list and interactive voice response system; preallocated block design (block size six); stratified by previous treatment with VEGF-targeting drugs, time from diagnosis of metastatic disease, and geographical region) to receive best supportive care plus oral regorafenib 160 mg or placebo once daily, for the first 3 weeks of each 4 week cycle...
January 26, 2013: Lancet
https://www.readbyqxmd.com/read/25337750/initial-therapy-with-folfoxiri-and-bevacizumab-for-metastatic-colorectal-cancer
#20
RANDOMIZED CONTROLLED TRIAL
Fotios Loupakis, Chiara Cremolini, Gianluca Masi, Sara Lonardi, Vittorina Zagonel, Lisa Salvatore, Enrico Cortesi, Gianluca Tomasello, Monica Ronzoni, Rosella Spadi, Alberto Zaniboni, Giuseppe Tonini, Angela Buonadonna, Domenico Amoroso, Silvana Chiara, Chiara Carlomagno, Corrado Boni, Giacomo Allegrini, Luca Boni, Alfredo Falcone
BACKGROUND: A fluoropyrimidine plus irinotecan or oxaliplatin, combined with bevacizumab (a monoclonal antibody against vascular endothelial growth factor), is standard first-line treatment for metastatic colorectal cancer. Before the introduction of bevacizumab, chemotherapy with fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) showed superior efficacy as compared with fluorouracil, leucovorin, and irinotecan (FOLFIRI). In a phase 2 study, FOLFOXIRI plus bevacizumab showed promising activity and an acceptable rate of adverse effects...
October 23, 2014: New England Journal of Medicine
label_collection
label_collection
4741
1
2
2015-06-19 07:31:35
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"